Roche
NEWS
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
Genentech, a Roche company, announced that its Phase III MINISTONE-2 clinical trial hit its primary endpoint, showing that its Xofluza (baloxavir marboxil) was comparable to its own Tamiflu (oseltamivir). It was also well-tolerated in children with the flu.
The public’s perception of the drug industry can be confusing. Recent studies take a hard look at the industry from different perspectives.
Rozlytrek is the first tumor-agnostic medicine approved in Japan for adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors.
Government agencies in the United States and U.K. are scrutinizing Roche’s planned acquisition of the gene therapy company.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
JOBS
IN THE PRESS